Clinical Trials Logo

Lung Cancer clinical trials

View clinical trials related to Lung Cancer.

Filter by:

NCT ID: NCT00898820 Completed - Lung Cancer Clinical Trials

Tumor Response to Pemetrexed Disodium in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Enrolled in Clinical Trial MCCRC-RC0524

Start date: November 2006
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of blood in the laboratory from patients receiving pemetrexed disodium may help doctors learn more about the effects of pemetrexed disodium on cells. It may also help doctors understand how well patients respond to treatment. PURPOSE: This laboratory study is looking at blood samples from patients with stage III or stage IV non-small cell lung cancer enrolled in clinical trial MCCRC-RC0524 to determine the effect of pemetrexed disodium on cells.

NCT ID: NCT00898417 Completed - Lung Cancer Clinical Trials

Biomarker Study of Blood Samples From Patients With Non-Small Cell Lung Cancer Treated With Carboplatin and Paclitaxel With or Without Bevacizumab

Start date: March 14, 2008
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of blood in the laboratory from patients undergoing treatment for non-small cell lung cancer may help doctors predict how patients will respond to treatment. PURPOSE: This laboratory study is looking at proteomic patterns in stored blood samples from patients undergoing treatment for non-small cell lung cancer.

NCT ID: NCT00898313 Recruiting - Lung Cancer Clinical Trials

Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer

Start date: December 2003
Phase:
Study type: Observational

RATIONALE: Using samples of blood, urine, sputum, and lung tissue from patients at high risk of cancer for laboratory studies may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at molecular predictors of cancer in patients at high risk of lung cancer.

NCT ID: NCT00898209 Terminated - Lung Cancer Clinical Trials

Serum and Exhaled Breath Condensate MALDI-MS of Lung Cancer. (SPORE)

Start date: April 2003
Phase: N/A
Study type: Observational

RATIONALE: Collecting and storing samples of blood and exhaled breath from patients with cancer and from healthy participants to study in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is collecting and analyzing samples of blood and exhaled breath from patients who have or are at high risk for lung cancer and from healthy participants.

NCT ID: NCT00897793 Completed - Breast Cancer Clinical Trials

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

Start date: January 2006
Phase: N/A
Study type: Observational

RATIONALE: Measuring levels of transforming growth factor-beta (TGF-beta) in the blood of patients with epithelial cancers (head and neck, lung, breast, colorectal, and prostate) may help doctors predict how patients will respond to treatment with radiation therapy. PURPOSE: This research study is measuring levels of TGF-beta in patients with epithelial cancers who are undergoing radiation therapy.

NCT ID: NCT00897650 Completed - Lung Cancer Clinical Trials

Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer

Start date: December 2005
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of tumor tissue and blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in genetic material (DNA and RNA) and may also identify protein expression patterns related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study evaluates changes in DNA, RNA, and proteins with the goal of predicting response to treatment in patients with lung cancer.

NCT ID: NCT00897533 Completed - Lung Cancer Clinical Trials

Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung Cancer

Start date: April 13, 2007
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients respond to treatment with erlotinib. PURPOSE: This laboratory study is developing a model to predict progression-free survival after erlotinib in patients with non-small cell lung cancer.

NCT ID: NCT00897364 Completed - Lung Cancer Clinical Trials

Biomarkers in the Nose, Throat, and Lung Tissue of Smokers and Non-Smokers

Start date: May 2000
Phase:
Study type: Observational

RATIONALE: Studying samples of tissue from smokers and non-smokers in the laboratory may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This phase II study is looking at biomarkers in the nose, throat, and lung tissue of smokers and non-smokers.

NCT ID: NCT00897234 Completed - Lung Cancer Clinical Trials

Blood Samples From Patients With Non-Small Cell Lung Cancer and From Healthy Volunteers

Start date: December 2008
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at blood samples from patients with non-small cell lung cancer and from healthy volunteers.

NCT ID: NCT00897143 Withdrawn - Lung Cancer Clinical Trials

Identifying Early Lung Cancer Cells in Malignant Pleural Effusion Samples From Patients With Primary Lung Cancer

Start date: June 2007
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of pleural fluid in the laboratory from patients with lung cancer may help doctors identify early lung cancer cells. It may also help the study of lung cancer in the future. PURPOSE: This laboratory study is looking at malignant pleural effusion samples from patients with primary lung cancer to see if early lung cancer cells can be identified.